Twitter Facebook LinkedIn YouTube

Videos Tagged: fsd pharma

FSD Pharma, a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced the submission of an Investigational New Drug or “IND” application with the U.S. Food and Drug Administration and Health Canada.
FSD Pharma, a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced the submission of an Investigational New Drug or “IND” application with the U.S. Food and Drug Administration and Health Canada.
FSD Pharma, a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has closed the sale of non-core assets for $16.4 million.
FSD Pharma, a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has closed the sale of non-core assets for $16.4 million.
FSD Pharma Enters into Firm Agreement to Sell Former Cannabis Processing Facility in Cobourg, Ontario for $16,500,000
FSD Pharma Enters into Firm Agreement to Sell Former Cannabis Processing Facility in Cobourg, Ontario for $16,500,000
FSD Pharma unveils videos demonstrating positive effects of Lucid-MS in treating multiple sclerosis in pre-clinical mouse models
FSD Pharma unveils videos demonstrating positive effects of Lucid-MS in treating multiple sclerosis in pre-clinical mouse models
FSD Pharma closed its acquisition of Canadian specialty psychedelic pharmaceutical company Lucid Psycheceuticals
FSD Pharma closed its acquisition of Canadian specialty psychedelic pharmaceutical company Lucid Psycheceuticals
FSD Pharma signs definitive agreement to acquire 100% of Lucid Psycheceuticals Inc.
FSD Pharma signs definitive agreement to acquire 100% of Lucid Psycheceuticals Inc.
FSD Pharma, a specialty, biotech pharmaceutical R&D company, has terminated its CEO, Dr. Raza Bokhari, for cause
FSD Pharma, a specialty, biotech pharmaceutical R&D company, has terminated its CEO, Dr. Raza Bokhari, for cause
Canntab receives Cannabis Standard Processing & Sales for Medical Purposes Licence from Health Canada
Canntab receives Cannabis Standard Processing & Sales for Medical Purposes Licence from Health Canada
Canntab Therapeutics has been granted a Cannabis Research Licence by Health Canada
Canntab Therapeutics has been granted a Cannabis Research Licence by Health Canada
Canntab signs term sheet with Heritage Cannabis to process hemp into high quality CBD oil for Canntab's gelcaps
Canntab signs term sheet with Heritage Cannabis to process hemp into high quality CBD oil for Canntab's gelcaps
Canntab receives cultivation licence for industrial hemp, secures 2 Canadian properties totaling 560 acres
Canntab receives cultivation licence for industrial hemp, secures 2 Canadian properties totaling 560 acres
Canntab Approaches Revenue with FSD Pharma's New
Canntab Approaches Revenue with FSD Pharma's New "Sale for Medical Purposes" Cannabis License
FSD Pharma and SciCann Therapeutics Launch Clinical Cannabis-based Research Program in Israel
FSD Pharma and SciCann Therapeutics Launch Clinical Cannabis-based Research Program in Israel
Canntab Therapeutics (CSE:PILL) has entered into a non-binding letter of intent with FSD Pharma Inc.
Canntab Therapeutics (CSE:PILL) has entered into a non-binding letter of intent with FSD Pharma Inc.